Incannex Healthcare Inc.

IXHL ·Healthcare, Drug Manufacturers - General
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-46.9M $-18.5M $-48.8M $-14.9M $-11.4M $-4.7M
Depreciation & Amortization $246.0K $103.0K $88.0K — — —
Depreciation $143.00B $103.00B $23.0M — — —
Amortization — — — — — —
Stock-Based Compensation $2.6M $8.9M $2.1M $1.5M $600.0K $565.4K
Net Cash from Operating Activities $-12.5M $-15.8M $-10.7M $-12.8M $-6.9M $-3.9M
Investing Activities
Capital Expenditures $8.0K $277.0K $316.0K — — —
Business Acquisitions — — — — — —
Net Cash from Investing Activities $-8.0K $-277.0K $-316.0K — $29.3K $13.0K
Financing Activities
Dividends Paid — — — — — —
Stock Repurchases — — — — — —
Net Cash from Financing Activities $21.4M — $8.2M $41.2M $12.4M $7.4M
Net Change in Cash — — — $28.4M $5.5M $3.5M
Free Cash Flow $-12.5M $-16.1M $-11.1M — — —